Abstract
In recent years, the maximization of blockbuster revenues has been compromised
by generic price erosion and a decline in new drug approvals. Large
pharmaceutical companies are coming under pressure to explore new R&D
strategies and implement more cost-effective sourcing methods for innovative
new molecules. The biotechnology industry is emerging as a hub of innovation
for biomarker and new chemical entity (NCE) identification, and has become a
vital component in the preclinical development of new drug technologies. As
therapy focus shifts to treating the causal pathway of disease and not merely
the symptomology, the majority of emerging targeted therapeutics are large
molecule biologics, while monoclonal antibody therapies represents the fastest
growing segment within the pharmaceutical industry. The Future of Targeted
Therapeutics: Key technologies, new therapy area applications and leading
players is a new report published by Business Insights that examines various
types of targeted therapy within pharma pipelines, highlighting the molecules
of greatest significance to major therapy areas. The key revenue drivers and
product focus within targeted technology markets are also assessed. This
report also measures the impact of the new model of targeted therapeutic
development upon stakeholder demand and health economics. Discover the most
promising targeted molecules within each therapeutic area, identify the
pipeline potential of leading companies and align your R&D strategies with the
latest innovations and development models...
| 
View Cart
